Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now known as Zeposia. A preliminary settlement of the 7-1/2-year-old class action was …
Howden Names Neumann Executive Vice President, Financial Lines Claims Leader
Howden named Elizabeth Neumann executive vice president and financial lines claims leader for its U.S. operations. She will be based in New York and will
